Terni

• C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant … Recruiting
  2024-511652-40-00 5 2025-02-05 METASTATIC CASTRATION RESISTANT PROSTATE CANCER
• “A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br … Recruiting
  2024-519514-31-00 4 2025-01-31 metastatic triple-negative PD-L1 positive breast cancer
• Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting
  2024-519310-31-00 4 2025-01-27 Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
• Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line … Recruiting
  2024-511945-20-00 4 2025-01-24 patients affected by small cell lung cancer (SCLC)
• PROSPECTIVE EVALUATION OF THE DDR GENES ALTERATION TO PREDICT RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED UROTHELIAL CANCER Recruiting
  2024-516450-21-00 6 2024-12-31 metastatic or locally advanced urothelial cancer
• Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting
  2024-514304-14-00 1 2024-10-08 Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 5 2023-12-14 Early stage Follicular Lymphoma
• A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting
  2024-513562-19-00 5 2023-08-30 End-Stage Kidney Disease
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate … Recruiting
  2024-511631-10-00 9 2023-02-27 Hodgkin’s lymphoma
• A continued study in patients with Hematologic Cancers previously treated with Tafasitamab. Recruiting
  2022-500765-27-00 5 2022-11-03 Hematologic malignancies
• An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients wit … Recruiting
  2024-511635-94-00 4 2022-07-11 Relapsed or Refractory Plasmablastic lymphoma
• Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants Wi … Recruiting
  2023-504599-10-00 4 2022-03-29 Chronic lymphocytic leukemia recurrent
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COM … Recruiting
  2024-516330-35-00 5 2021-09-29 Non-Small Cell Lung Cancer
• Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Recruiting
  2024-514824-18-00 4 2021-09-16 chronic lymphocytic leukemia/small lymphocytic lymphoma
• RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line … Recruiting
  2024-518623-30-00 6 2020-10-01 metastatic castration resistant prostate cancer without mutations of B
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended recruitment
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma

Showing 25–48 of 100 trials